Janux Therapeutics, Inc. (JANX)
18.05
-0.73
(-3.89%)
USD |
NASDAQ |
Aug 28, 15:56
Janux Therapeutics Gross Profit Margin (Quarterly) : 95.49% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 95.49% |
| March 31, 2026 | 87.44% |
| December 31, 2025 | |
| September 30, 2025 | 94.99% |
| June 30, 2025 | |
| March 31, 2025 | |
| December 31, 2024 | |
| September 30, 2024 | -16.17% |
| June 30, 2024 | 94.31% |
| March 31, 2024 | 57.51% |
| December 31, 2023 | 78.42% |
| Date | Value |
|---|---|
| September 30, 2023 | 80.14% |
| June 30, 2023 | 55.44% |
| March 31, 2023 | 77.88% |
| December 31, 2022 | 85.83% |
| September 30, 2022 | 86.27% |
| June 30, 2022 | 95.43% |
| March 31, 2022 | 94.90% |
| December 31, 2021 | 96.04% |
| September 30, 2021 | 0.00% |
| June 30, 2021 | 0.00% |
| March 31, 2021 | 97.63% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| MacroGenics, Inc. | 97.84% |
| Agenus, Inc. | 98.50% |
| Amgen, Inc. | 72.08% |
| Anika Therapeutics, Inc. | 65.15% |
| BioCryst Pharmaceuticals, Inc. | 98.01% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -10.70% |
| Return on Assets | -10.06% |
| Return on Invested Capital | -10.46% |
| Profit Margin (Quarterly) | -214.0% |
| Operating Margin (Quarterly) | -308.7% |
| Return on Net Operating Assets | -311.6% |